Cargando…
PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study
PURPOSE: Treatment decision making for patients with breast cancer increasingly depends on analysis of markers or systems for estimating risk of breast cancer recurrence. Breast cancer intrinsic subtypes and risk of recurrence (ROR) scores have been found to be valuable in predicting survival and de...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300149/ https://www.ncbi.nlm.nih.gov/pubmed/37266756 http://dx.doi.org/10.1007/s10549-023-06969-1 |
_version_ | 1785064525426327552 |
---|---|
author | Phakathi, Boitumelo Dix-Peek, Therese Van Den Berg, Eunice Dickens, Caroline Nietz, Sarah Cubasch, Herbert Joffe, Maureen Neugut, Alfred I. Jacobson, Judith S. Ruff, Paul Duarte, Raquel |
author_facet | Phakathi, Boitumelo Dix-Peek, Therese Van Den Berg, Eunice Dickens, Caroline Nietz, Sarah Cubasch, Herbert Joffe, Maureen Neugut, Alfred I. Jacobson, Judith S. Ruff, Paul Duarte, Raquel |
author_sort | Phakathi, Boitumelo |
collection | PubMed |
description | PURPOSE: Treatment decision making for patients with breast cancer increasingly depends on analysis of markers or systems for estimating risk of breast cancer recurrence. Breast cancer intrinsic subtypes and risk of recurrence (ROR) scores have been found to be valuable in predicting survival and determining optimal treatment for individual patients. We studied the association of breast cancer survival with the PAM50 gene expression assay in HIV-positive and HIV-negative patients. METHOD: RNA was extracted from formalin-fixed paraffin-embedded specimens of histologically confirmed invasive carcinoma and was purified using the AllPrep® DNA/RNA FFPE kit, Qiagen (Hilden, Germany). The NanoString RUO PAM50 algorithm was used to determine the molecular subtype and the risk of recurrence score of each sample. The overall and disease-free survival were determined with comparison made among HIV-positive and -negative patients. We then generated Kaplan–Meier survival curves, calculated p-values and estimated hazard ratios and their 95% confidence intervals using Cox regression models. RESULTS: Of the 384 RNA samples analysed, 98.4% met the required RNA quality standard and the specified QC threshold for the test. Luminal B was the most common PAM50 intrinsic subtype and 82.1% of patients were at high risk for disease recurrence based on ROR score. HIV infection, PAM50-based HER2-enriched and basal-like intrinsic subtypes, and high ROR were associated with poor overall and disease-free survival. HIV-positive patients with luminal A & B subtypes had significantly worse survival outcomes than HIV-negative luminal patents. CONCLUSION: Aggressive tumour biology was common in our cohort. HIV infection, PAM50 HER2-enriched,basal-like intrinsic subtypes and high ROR score were associated with poor overall and disease-free survival. HIV infection impacted survival in patients with luminal subtypes only. |
format | Online Article Text |
id | pubmed-10300149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-103001492023-06-29 PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study Phakathi, Boitumelo Dix-Peek, Therese Van Den Berg, Eunice Dickens, Caroline Nietz, Sarah Cubasch, Herbert Joffe, Maureen Neugut, Alfred I. Jacobson, Judith S. Ruff, Paul Duarte, Raquel Breast Cancer Res Treat Original Laboratory Investigation PURPOSE: Treatment decision making for patients with breast cancer increasingly depends on analysis of markers or systems for estimating risk of breast cancer recurrence. Breast cancer intrinsic subtypes and risk of recurrence (ROR) scores have been found to be valuable in predicting survival and determining optimal treatment for individual patients. We studied the association of breast cancer survival with the PAM50 gene expression assay in HIV-positive and HIV-negative patients. METHOD: RNA was extracted from formalin-fixed paraffin-embedded specimens of histologically confirmed invasive carcinoma and was purified using the AllPrep® DNA/RNA FFPE kit, Qiagen (Hilden, Germany). The NanoString RUO PAM50 algorithm was used to determine the molecular subtype and the risk of recurrence score of each sample. The overall and disease-free survival were determined with comparison made among HIV-positive and -negative patients. We then generated Kaplan–Meier survival curves, calculated p-values and estimated hazard ratios and their 95% confidence intervals using Cox regression models. RESULTS: Of the 384 RNA samples analysed, 98.4% met the required RNA quality standard and the specified QC threshold for the test. Luminal B was the most common PAM50 intrinsic subtype and 82.1% of patients were at high risk for disease recurrence based on ROR score. HIV infection, PAM50-based HER2-enriched and basal-like intrinsic subtypes, and high ROR were associated with poor overall and disease-free survival. HIV-positive patients with luminal A & B subtypes had significantly worse survival outcomes than HIV-negative luminal patents. CONCLUSION: Aggressive tumour biology was common in our cohort. HIV infection, PAM50 HER2-enriched,basal-like intrinsic subtypes and high ROR score were associated with poor overall and disease-free survival. HIV infection impacted survival in patients with luminal subtypes only. Springer US 2023-06-02 2023 /pmc/articles/PMC10300149/ /pubmed/37266756 http://dx.doi.org/10.1007/s10549-023-06969-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Laboratory Investigation Phakathi, Boitumelo Dix-Peek, Therese Van Den Berg, Eunice Dickens, Caroline Nietz, Sarah Cubasch, Herbert Joffe, Maureen Neugut, Alfred I. Jacobson, Judith S. Ruff, Paul Duarte, Raquel PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study |
title | PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study |
title_full | PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study |
title_fullStr | PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study |
title_full_unstemmed | PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study |
title_short | PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study |
title_sort | pam50 intrinsic subtypes, risk of recurrence score and breast cancer survival in hiv-positive and hiv-negative patients—a south african cohort study |
topic | Original Laboratory Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300149/ https://www.ncbi.nlm.nih.gov/pubmed/37266756 http://dx.doi.org/10.1007/s10549-023-06969-1 |
work_keys_str_mv | AT phakathiboitumelo pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy AT dixpeektherese pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy AT vandenbergeunice pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy AT dickenscaroline pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy AT nietzsarah pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy AT cubaschherbert pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy AT joffemaureen pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy AT neugutalfredi pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy AT jacobsonjudiths pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy AT ruffpaul pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy AT duarteraquel pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy |